Zacks Investment Research upgraded shares of INDIVIOR PLC/S (OTCMKTS:INVVY) from a hold rating to a buy rating in a report published on Tuesday. Zacks Investment Research currently has $15.00 price target on the stock.
According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “
Separately, ValuEngine raised INDIVIOR PLC/S from a sell rating to a hold rating in a research note on Tuesday, July 17th.
INDIVIOR PLC/S (OTCMKTS:INVVY) last announced its quarterly earnings results on Thursday, July 26th. The company reported $0.45 EPS for the quarter. The business had revenue of $268.00 million during the quarter. As a group, analysts expect that INDIVIOR PLC/S will post 1.89 EPS for the current fiscal year.
INDIVIOR PLC/S Company Profile
Indivior PLC is a holding company, which engages in the manufacture and distribution of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, and Sublocade Injection. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.